BCL2L1 and Thrombocytopenia: For example ABT-263 (Navitoclax), an inhibitor of BCL2 has shown clinical efficacy in many haematological cancers, but it causes thrombocytopenia due to interaction with other BCL2 family proteins like BCL-XL and BCL-W24.